A group of long-time stockholders (the “Nominating Stockholders” or the “Group”) of CytoDyn Inc. (“CYDY or the “Company”) (OTC: CYDY)
Read more
Company Believes All Issues Are Addressable and it Will Be Able to Continue BLA Resubmission CMC and Non-Clinical Sections Will
Read more
CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for
Read more
VANCOUVER, Washington, July 19, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab,
Read more
VANCOUVER, Washington, July 06, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more
VANCOUVER, Washington, May 27, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more
Interim analysis for critically ill population will be conducted when enrollment reaches about 120 patients or 40% of the approximate
Read more
VANCOUVER, Washington, April 05, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more
Trial commencement will be expedited by enrolling patients in Brazil, U.K., and Canada while immediate EUA requests are pursued in
Read more
Clinical outcome improvement (based on ordinal scale) with leronlimab at day 14 was 400% better than placebo arm with p-value
Read more
CD12 trial results also indicated that five out of six patients on ECMO recovered VANCOUVER, Washington, March 29, 2021 (GLOBE
Read more
VANCOUVER, Washington, March 08, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more